The global charcot marie tooth disease type 1 A drug market is anticipated to grow at a significant CAGR during the forecast period. Charcot-Marie-Tooth disease type 1A (CMT1A) is a type of inherited neurological disorder that affects the peripheral nerves. People with this disease experience weakness and wasting (atrophy) of the muscles of the lower legs beginning in adolescence; later they can also have hand weakness and sensory loss. While the involvement of the central nervous system in clinical phenotype of patients with charcot marie tooth disease has been reported in the past, its association with epilepsy has also been witnessed. A few patients with charcot marie tooth are reported to have epilepsy. According to the World Health Organization (WHO) epilepsy is a chronic non-communicable disease of the brain that affects people of all ages. As of 2019, nearly 50 million people across the globe had epilepsy. This makes epilepsy as one of the most common neurological diseases globally.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/charcot-marie-tooth-disease-type-1-a-drug-market
Moreover, as per the WHO, it is also estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated. The risk of premature mortalities in people with epilepsy is up to three times higher than for the general population. Although there is no complete cure discovered for charcot marie tooth disease, various researches investigating various pharmacological modulators of adenylyl cyclase activity, including ascorbic acid and ligands of G protein?coupled receptors (GPCRs), provide hope for future treatments of this type of hereditary motor and sensory neuropathy.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Product Type
o By Application
- Regions covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape: Sanofi S.A., and Addex Therapeutics, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Charcot Marie Tooth Disease Type 1 A Drug Market Report by Segment
By Product Type
- ADX-71441
- AFC-5128
- Others
By Application
- Hospital
- Clinic
- Others
A full report of Charcot Marie Tooth Disease Type 1 A Drug Market is available at: https://www.omrglobal.com/industry-reports/charcot-marie-tooth-disease-type-1-a-drug-market
Charcot Marie Tooth Disease Type 1 A Drug Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Sanofi S.A.
- Addex Therapeutics
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
